All Eyes on PCS - Analysis of the Retinal Microvasculature in Patients With Post-COVID-19 Syndrome
Launched by TECHNICAL UNIVERSITY OF MUNICH · Nov 30, 2022
Trial Information
Current as of June 20, 2025
Unknown status
Keywords
ClinConnect Summary
The investigators will recruit patients with PCS, fully COVID-19 recovered participants and COVID-19 infection naïve participants. After comprehensive clarification and given written informed consent, measurements will take place in the Klinikum rechts der Isar. To evaluate the retinal microvasculature dynamic retinal vessel analysis (DVA) and optical coherence tomography (OCT) are used. Patient reported outcomes (PROM) of PCS typical symptoms will be collected using standardized questionnaires. To ensure data quality the investigators will use standard operating procedures (SOP) for both t...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with Post-COVID syndrome (positive PCR or positive rapid antibody test ≥3 months) with a currently existing, PCS-typical complaint complex, ongoing for at least 2 months and cannot be explained by an alternative diagnosis.
- • Control group: recovered from COVID-19 infection (positive PCR or positive rapid antibody test ≥ 3 months) without residual symptoms.
- • Healthy cohort: no history of COVID-19 infection
- Exclusion Criteria:
- • Missing or incomplete consent form
- • Age \< 18 years
- • Pregnancy
- • Malignancy
- • Diseases associated with a significant change in life expectancy
- • Autoimmune diseases of the rheumatological type
- • Cataract
- • Epilepsy
- • Glaucoma
About Technical University Of Munich
The Technical University of Munich (TUM) is a leading research institution in Germany, renowned for its commitment to excellence in education, innovation, and technology transfer. With a strong emphasis on interdisciplinary collaboration, TUM fosters advancements in various fields, including medicine and life sciences. The university actively engages in clinical research, aiming to translate scientific discoveries into practical applications that improve patient outcomes. Through its state-of-the-art facilities and a network of partnerships with hospitals and industry, TUM is dedicated to conducting rigorous clinical trials that adhere to the highest ethical standards and contribute significantly to the advancement of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
München, Bavaria, Germany
Patients applied
Trial Officials
Christoph Schmaderer, Prof. Dr.
Principal Investigator
Technical University Munich
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials